# Healsun Biopharm

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/healsun-biopharm

- Industry: Pharmaceuticals
- Headquarters: Hangzhou, China
- Website: www.hs-biopharm.com
- Total disclosed funding: $77M
- Latest round: Series C (Nov 19, 2025)
- Investors on record: 12

## About

Based in Hangzhou, China and established in 2015, Healsun Biopharm is a pharmaceutical company that focuses on technology for antibody and recombinant protein drug development. The company raised RMB 80 million in series A funding. The company has R&D centers and manufacturing facilities in Shanghai and Hangzhou. As of 2023, it has more than 180 employees. In November 2025, Healsun Biopharm closed a Series C funding from new investors Linping SDIC, Beijia Investment Management, and Lujiazui (Zhejiang) Assets Management.

The company provides biopharmaceutical technology research and development services including antibody drug analysis, protein transient expression, antibody recombinant protein CMC development (stable cell line development, fermentation process development, purification process development, protein analysis method development and pilot production), antibody-conjugated drugs (ADCs) development and other technologies.

The company will use the series B+ funding to expand human resources, as well as to expand the commercialization pipeline of antibodies, recombinant proteins and ADC (antibody drug conjugates) drugs. In 2024 the company will have six 2,000L drug discovery and development lines in operation.

## Funding rounds

- Series C, Nov 19, 2025 — Lujiazui (Zhejiang) Assets Management, Beijia Investment Management, Linping SDIC
- Series B, Oct 7, 2023, $28M — Orient Jiafu Asset Management, CMS Ventures
- Series B, Aug 18, 2022, $37M — Haibang Venture, Yinxinggu Capital, Orient Jiafu Asset Management, Haitong Kaiyuan, Shanghai Biomedical Fund, Zhejiang Xinghua Dingli Private Equity Fund Management
- Series A, Apr 12, 2021, $12M — Sinowisdom, Haibang Venture, Yinxinggu Capital, Kington Capital

## Investors

- Sinowisdom (https://capitalatlas.ai/funds/sinowisdom) — Series A
- Haibang Venture — Series A, Series B
- Yinxinggu Capital (https://capitalatlas.ai/funds/yinxinggu-capital) — Series A, Series B
- Kington Capital (https://capitalatlas.ai/funds/kington-capital) — Series A
- Orient Jiafu Asset Management (https://capitalatlas.ai/funds/orient-jiafu-asset-management) — Series B
- Haitong Kaiyuan — Series B
- Shanghai Biomedical Fund — Series B
- Zhejiang Xinghua Dingli Private Equity Fund Management — Series B
- CMS Ventures (https://capitalatlas.ai/funds/cms-ventures) — Series B
- Lujiazui (Zhejiang) Assets Management (https://capitalatlas.ai/funds/lujiazui-zhejiang-assets-management) — Series C
- Beijia Investment Management (https://capitalatlas.ai/funds/beijia-investment-management) — Series C
- Linping SDIC — Series C